Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.

Gandhi, Sanjay K; Jensen, Marie M; Fox, Kathleen M; Smolen, Lee; Olsson, Anders G; Paulsson, Thomas

Gandhi, Sanjay K; Jensen, Marie M; Fox, Kathleen M; Smolen, Lee; Olsson, Anders G; Paulsson, Thomas.

Afiliação

Gandhi SK; AstraZeneca LP, Wilmington, DE, USA.

Clinicoecon Outcomes Res ; 4: 1-11, 2012.

Article em En | MEDLINE | ID: mdl-22347800

Palavras-chave

atorvastatin; cardiovascular disease; cost-benefit analysis; cost-effectiveness; generic; high risk; rosuvastatin; simvastatin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2012 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google